Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Oncopeptides AB ( (SE:ONCO) ) has provided an announcement.
Oncopeptides’ Annual General Meeting approved the 2025 annual report, discharged the board and CEO from liability, confirmed the allocation of results, and re-elected key board members, including Chairman Per Wold-Olsen, alongside the company’s auditor. Shareholders also endorsed the remuneration report, updated guidelines for senior management pay, and fee levels for the board, its committees, and the auditor.
The AGM adopted a new share-based RSU program for independent board members and a performance-based long-term incentive plan for employees and consultants that could together allocate up to 6.2 million ordinary shares, aligning compensation with share price performance and board service. The meeting further authorized the board to issue new shares, warrants, and convertibles with potential dilution of up to 20%, enhancing Oncopeptides’ financial flexibility to fund acquisitions or project development without always relying on shareholders’ preferential rights.
More about Oncopeptides AB
Oncopeptides AB is a Stockholm-based biopharmaceutical company listed on Nasdaq Stockholm under the ticker ONCO. The company focuses on developing and commercializing cancer treatments, with a particular emphasis on therapies for hematological malignancies, positioning itself within the oncology segment of the life sciences sector.
Average Trading Volume: 5,181,480
Technical Sentiment Signal: Sell
Current Market Cap: SEK757.1M
Find detailed analytics on ONCO stock on TipRanks’ Stock Analysis page.